{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T18:29:46Z","timestamp":1649183386370},"reference-count":15,"publisher":"Japan Society for Clinical Immunology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2004]]},"DOI":"10.2177\/jsci.27.156","type":"journal-article","created":{"date-parts":[[2005,2,16]],"date-time":"2005-02-16T01:04:12Z","timestamp":1108515852000},"page":"156-163","source":"Crossref","is-referenced-by-count":1,"title":["Opportunistic Infections"],"prefix":"10.2177","volume":"27","author":[{"given":"Katsuhiko","family":"TAKABAYASHI","sequence":"first","affiliation":[{"name":"Department of Medical Informatics and Management, Chiba University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"HANAOKA","sequence":"additional","affiliation":[{"name":"Center of Clinical Research, Chiba University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Dale DC., Petersdorf RG. : Corticosteroids and infectious diseases. Med Clin North Am. 57 : 1277-1287, 1973.","DOI":"10.1016\/S0025-7125(16)32228-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Stuck AE., Minder CE., Frey FJ. : Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 11 : 954-963, 1989.","DOI":"10.1093\/clinids\/11.6.954"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Boumpas DT., Chrousos GP., Wilder RL. : Glucocorticoid therapy for immune-mediated diseases : basic and clinical correlates. Ann Intern Med. 119 : 1198-1208, 1993.","DOI":"10.7326\/0003-4819-119-12-199312150-00007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pryor BD., Bologna SG., Kahl LE. : Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 39 : 1475-1482, 1996.","DOI":"10.1002\/art.1780390906"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Mok CC., Lee KW., Ho CT. : A prospective study of survival and prognostic indications of systemic lupus erythematosus in a southern Chinese population. Rheumatology. 39 : 399-406, 2000.","DOI":"10.1093\/rheumatology\/39.4.399"},{"key":"6","doi-asserted-by":"crossref","unstructured":"9) Gardam MA., Keystone EC., Menzies R. : Anti-tumour necrosis factor agents and tuberculosis risk : mechanisms of action and clinical management. Lancet Infect Dis. 3 : 148-55, 2003.","DOI":"10.1016\/S1473-3099(03)00545-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"10) Newsome G. : Guideline for the management of Rheumatoid Arthritis, 2002 update. Arthritis Rheum. 46 : 328-346, 2002.","DOI":"10.1002\/art.10148"},{"key":"8","doi-asserted-by":"crossref","unstructured":"14) Keane J., Gershon S., Wise RP., et al. : Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 345 : 1098-1104, 2001.","DOI":"10.1056\/NEJMoa011110"},{"key":"9","doi-asserted-by":"crossref","unstructured":"15) Wolfe F., Michaud K., Anderson J. : Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50 : 372-379, 2004.","DOI":"10.1002\/art.20009"},{"key":"10","doi-asserted-by":"crossref","unstructured":"16) Gomez-Reino JJ., Carmona L., Valverde VR. : Treatment of Rheumatoid Arthritis With Tumor Necrosis Factor Inhibitors May Predispose to Significant Increase in Tuberculosis Risk. Arthritis Rheum. 48 : 2122-2127, 2003.","DOI":"10.1002\/art.11137"},{"key":"11","unstructured":"17) WHO Report 2003, Global Tuberculosis Control Communicable Diseases. WHO, 2003."},{"key":"12","doi-asserted-by":"crossref","unstructured":"18) Ward MM., Donald F. : Pneumocystis carinii pneumonia in patients with connective tissue diseases : the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 42 : 780-789, 1999.","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M"},{"key":"13","unstructured":"19) Godeau B., Coutant-Perronne V., Le Thi Huong D : Pneumocystis carinii pneumonia in the course of connective tissue disease : report of 34 cases. J Rheumatol. 21 : 246-51, 1994."},{"key":"14","doi-asserted-by":"crossref","unstructured":"20) Tai TL., O&rsquo;Rourke KP., McWeeney M. : Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology. 41 : 951-952, 2002.","DOI":"10.1093\/rheumatology\/41.8.951"},{"key":"15","doi-asserted-by":"crossref","unstructured":"21) Contreras G., Pardo V., Leclercq B. : Sequential Therapies for Proliferative Lupus Nephritis. N Engl J Med. 350 : 971-980, 2004.","DOI":"10.1056\/NEJMoa031855"}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u65e5\u548c\u898b\u611f\u67d3\u75c7"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/27\/3\/27_3_156\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T11:56:36Z","timestamp":1497614196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/27\/3\/27_3_156\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.27.156","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}